Schizophrenia: assessment and continuing treatment
Schizophrenia can affect perception, thinking, motivation and daily functioning. An Ondoc clinician can discuss symptoms or an established treatment plan and help coordinate appropriate psychiatric care.
What your visit can cover
- Review psychotic symptoms, functioning and the previous diagnostic assessment
- Discuss antipsychotic response, adverse effects and continuity of treatment
- Identify psychiatric follow-up, psychosocial support and urgent-care needs
When to be seen in person
A first episode of psychosis or rapidly worsening hallucinations, confusion or inability to care for yourself needs urgent in-person assessment. Call 911 for immediate danger; call or text 988 for crisis support.
About Schizophrenia
Symptoms can include hallucinations, delusions, disorganized thought or speech, reduced motivation and expression, and cognitive difficulties. Schizophrenia is not a split personality. Diagnosis requires assessment of duration, functional change and other possible causes, including mood disorders, substances and medical illness. Antipsychotic medication is a core treatment; coordinated specialty care for early psychosis, family education, supported work or education and psychotherapy can help recovery. Continuing psychiatric follow-up addresses relapse, physical health and adverse effects. Ondoc can discuss care and referral but does not promise an early-psychosis program, injectable administration or a psychiatrist on every visit.
Additional medication information
Educational options, not an offer of a prescription from every provider. No dose or ordering instruction is provided.
- Antipsychotic medicines
- Lurasidone and cariprazine have FDA-approved schizophrenia indications. Strengths listed include 20, 40 and 80 mg for lurasidone and 1.5, 3 and 4.5 mg for cariprazine; these are not dosing instructions or a promise of prescribing. Food requirements, interactions and movement/metabolic effects differ.
- Clozapine and injectable treatments
- Clozapine has a role in treatment-resistant schizophrenia and reducing recurrent suicidal behavior in selected patients with schizophrenia or schizoaffective disorder. It requires specialized monitoring. Long-acting antipsychotic injections have product-specific indications and administration arrangements; discuss access and follow-up with the treating specialist.